The Center of Excellence for External Drug Discovery

Quick Links

what is the ceedd?

why work with us?

what are we looking for?

"We've got 20,000 scientists fishing for ideas in our lake - if there's a fish, then we're going to catch it. The trick is now to go out and cast the line in other people's lakes to find their exciting scientific programs." Jean-Pierre Garnier, CEO GlaxoSmithKline

To make this vision a reality, GlaxoSmithKline (GSK) has created a small management team whose goal it is to supplement the GSK pipeline with assets developed through external alliances. This team is called the Center of Excellence for External Drug Discovery or CEEDD. In essence, we will "virtualize" a portion of the GSK pipeline; namely, from target to clinical proof of concept, by forming multiple risk/reward-sharing alliances with world-class biotechnology companies. Combining the speed, efficiency and innovation of collaborating companies with GSK’s development and commercialization expertise will bring innovative new products to more patients more quickly.

SEEDD News

10 Dec 2007 - GlaxoSmithKline And OncoMed Pharmaceuticals Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics
GlaxoSmithKline (GSK) and OncoMed Pharmaceuticals (OncoMed) today announced a worldwide strategic alliance to discover, develop and market novel antibody therapeutics to target cancer stem cells which are believed to play a key role in the establishment, metastasis and recurrence of cancer. The alliance with GSK will be conducted through its Center of Excellence for External Drug Discovery (CEEDD).
complete article »

Horz Div

27 Jul 2007 - GlaxoSmithKline and Targacept Form Alliance in Therapeutics for CNS-related Disorders
GlaxoSmithKline (GSK) and Targacept, Inc. (NASDAQ: TRGT) today announced a strategic alliance to discover, develop and market novel therapeutics that selectively target specified neuronal nicotinic receptors (NNRs).

complete article »

Alliance News

13 May 2008 - ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 Drug Represents Potential New Approach for the Treatment of Inflammatory Disease
ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX354, an orally-available, novel small molecule compound designed to specifically target the CCR1 chemokine receptor which is associated with inflammatory diseases such as rheumatoid arthritis. With the dosing of the first patient in this trial, ChemoCentryx will be entitled to receive a $10 million milestone payment from alliance partner GlaxoSmithKline (NYSE: GSK).

complete article »

Horz Div

6 May 2008 - Company Earns $7.5 Million Milestone From GlaxoSmithKline
EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it has begun its Phase 2b program in Alzheimer's disease through the initiation of a clinical trial of PRX-03140, its novel 5-HT4 agonist, in combination with donepezil (Aricept(R)).
complete article »